Bluejay Diagnostics (BJDX) rotates Board and committee chair positions
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. reported that its Board of Directors updated leadership roles on the Board and its key committees, effective August 15, 2025. Donald R. Chase was appointed Chairperson of the Board, succeeding Douglas C. Wurth. Mr. Wurth became Chairperson of the Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman, and Mr. Zeidman was named Chairperson of the Compensation Committee, succeeding Mr. Chase.
Mr. Chase continues to serve as Chairperson of the Audit Committee, and all three standing Board committees remain composed of Messrs. Chase, Wurth, and Zeidman. The Board describes these changes as part of its periodic review of governance assignments and notes that all three directors are considered independent under Nasdaq listing rules and Rule 10A-3 under the Securities Exchange Act of 1934.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01 | Other Events. |
On August 15, 2025, the Board of Directors (the “Board”) of Bluejay Diagnostics, Inc. unanimously approved the following Board and committee Chair appointments, effective immediately: (i) Donald R. Chase as Chairperson of the Board (succeeding Douglas C. Wurth); (ii) Mr. Wurth as Chairperson of the Nominating and Corporate Governance Committee of the Board (succeeding Fred S. Zeidman), and (iii) Mr. Zeidman as Chairperson of the Compensation Committee of the Board (succeeding Mr. Chase). Mr. Chase remains Chairperson of the Audit Committee of the Board, and each of the three standing Board committees remain comprised of Messrs. Chase, Wurth and Zeidman. The foregoing Chair appointments were made as part of the Board’s periodic review and consideration of Board and committee governance assignments. Each of Messrs. Chase, Wurth and Zeidman have been determined by the Board to be independent under applicable Nasdaq listing rules, and to satisfy the independence criteria under Rule 10A-3 under the Securities Exchange Act of 1934, as amended.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Bluejay Diagnostics, Inc. | ||
| By: | /s/ Neil Dey | |
| Neil Dey | ||
| President and Chief Executive Officer | ||
Date: August 15, 2025
2
FAQ
What Board leadership changes did Bluejay Diagnostics (BJDX) announce?
Bluejay Diagnostics appointed Donald R. Chase as Chairperson of the Board, with Douglas C. Wurth and Fred S. Zeidman rotating into new committee chair roles on August 15, 2025.
Who is now Chairperson of the Board at Bluejay Diagnostics (BJDX)?
Donald R. Chase is now Chairperson of the Board, succeeding Douglas C. Wurth, effective August 15, 2025.
How were Bluejay Diagnostics’ (BJDX) Board committee chair roles reallocated?
Douglas C. Wurth became Chairperson of the Nominating and Corporate Governance Committee, and Fred S. Zeidman became Chairperson of the Compensation Committee. Donald R. Chase remains Chairperson of the Audit Committee.
Did the composition of Bluejay Diagnostics’ (BJDX) Board committees change?
No. The three standing Board committees remain comprised of Messrs. Chase, Wurth, and Zeidman; only the Chair roles rotated.
Are Bluejay Diagnostics (BJDX) directors considered independent?
The Board determined that Chase, Wurth, and Zeidman are independent under applicable Nasdaq listing rules and meet the independence criteria under Rule 10A-3 of the Securities Exchange Act of 1934.
Why did Bluejay Diagnostics (BJDX) change its Board and committee chairs?
The company states that the Chair appointments were made as part of the Board’s periodic review and consideration of governance assignments.
